Media headlines about Neos Therapeutics (NASDAQ:NEOS) have been trending somewhat positive this week, Accern reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Neos Therapeutics earned a coverage optimism score of 0.15 on Accern’s scale. Accern also gave media headlines about the company an impact score of 46.4284327257063 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

A number of analysts have commented on the company. Cantor Fitzgerald reissued a “buy” rating and set a $20.00 price objective on shares of Neos Therapeutics in a report on Tuesday, September 26th. Royal Bank Of Canada set a $12.00 price objective on Neos Therapeutics and gave the stock an “outperform” rating in a report on Tuesday, August 8th. ValuEngine raised Neos Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 12th. BMO Capital Markets reissued an “outperform” rating and set a $15.00 price objective on shares of Neos Therapeutics in a report on Tuesday, June 20th. Finally, Zacks Investment Research lowered Neos Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 12th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $13.83.

Neos Therapeutics (NASDAQ:NEOS) opened at 8.70 on Friday. The company’s market capitalization is $244.30 million. The stock has a 50 day moving average price of $8.90 and a 200 day moving average price of $8.90. Neos Therapeutics has a 12-month low of $4.85 and a 12-month high of $9.60.

Neos Therapeutics (NASDAQ:NEOS) last announced its quarterly earnings data on Tuesday, August 8th. The company reported ($0.83) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.83). Neos Therapeutics had a negative net margin of 511.74% and a negative return on equity of 611.78%. The company had revenue of $4.91 million during the quarter. On average, analysts expect that Neos Therapeutics will post ($3.10) EPS for the current year.

TRADEMARK VIOLATION WARNING: “Neos Therapeutics (NEOS) Getting Somewhat Favorable Media Coverage, Report Finds” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at

Neos Therapeutics Company Profile

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Insider Buying and Selling by Quarter for Neos Therapeutics (NASDAQ:NEOS)

Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with's FREE daily email newsletter.